OVERVIEW
Dual anti-human epidermal growth factor receptor 2 (HER2) blockade has improved the outcomes of patients with early and metastatic HER2-positive breast cancer. The final 10-year analysis of the ALTTO trial is presented here.
study details
The Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (ALTTO) trial is the first large prospective randomised trial to report three anti-HER2 strategies that incorporated lapatinib and trastuzumab and compared these with trastuzumab alone as adjuvant therapy for patients with early-stage HER2-positive breast cancer.
TITLE OF PUBLICATION
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]
AUTHORS
de Azambuja E, Piccart-Gebhart M, Fielding S, Townend J, , Hillman, D.W, Colleoni M, Roylance R, KellyC.M. , Lombard J, El-Abed S, Choudhury A, Korde K, Vicente M, Chumsri S, Rodeheffer R, Ellard S.L., Wolff A.C., Holtschmidt J., Lang I, Untch M, Boyle F, Xu B, Werutsky G, Tujakowski J, Huang C.-S, Baruch N.B., Bliss J., Ferro A., GralowJ., Kim S.-B., Kroep J.R., Krop I., Kuemmel S., McConnell R., Moscetti L., Knop A.S., van Duijnhoven F., Gomez H., Cameron D., Di Cosimo S., Gelber R.D., Moreno-Aspitia A.
Publication Reference
ESMO Open | Volume 9 | Issue 11 | 103938 | November 2024
Marion Procter
Marion is a Senior Statistician who has worked in clinical trials at FSS since 2002.
The research area of her PhD thesis was the influence of missing explanatory variables and longitudinal assessments.
Her work in breast cancer trials includes collaborating on the statistical analysis plan and protocol amendments, producing reports for the data monitoring committee, preparing manuscripts for publication and working with investigators on research projects. The first efficacy results from the breast cancer trials were published in the New England Journal of Medicine. Research projects from these trials have been published in several journals including the Journal of Clinical Oncology.
Statistical methods in research projects include competing risks in survival analysis and nested case control analysis.
Marion has been a statistical review for scientific journals and has been accepted as the Independent Statistician for the RaTIO trial in oncology.
